Rising AI Healthcare Company Expanding Across the United States

The intersection of artificial intelligence (AI) and healthcare is rapidly reshaping the industry landscape, and Rocket Doctor AI (CSE: AIDR, OTC: AIRDF) is a prime example of the paradigm shift taking place in North America. For investors seeking high-growth opportunities in digital health, we believe Rocket Doctor AI stands out for its rapid expansion, impressive operating metrics, and recent major partnership and funding announcements.

Rapid Growth, New Partnerships, and National Reach

Just this year, Rocket Doctor AI has made a series of bold strategic moves that put it on investors’ radars. Perhaps most notably, the company recently signed contracts with six major U.S. insurance companies, unlocking in-network access for over 7 million patients spanning California and New York across Medicare Advantage, Medicaid Managed Care, and commercial health plans. Adding millions of covered lives in the largest and most dynamic healthcare markets not only accelerates expansion, but it also validates Rocket Doctor’s capability to work closely with mainstream payers and deliver scalable, differentiated and reimbursable virtual care.

This coverage win follows another major access milestone: Rocket Doctor now serves Medicaid and Medicare populations in Maryland, furthering its mission to make advanced, technology-driven healthcare available to some of the country’s most vulnerable and underserved patients. These partnerships position Rocket Doctor AI as an emerging force in both public and commercial virtual care delivery, pushing far beyond the limited reach of traditional telehealth.

Revenue Inception and High Margins

Rocket Doctor AI’s business story in 2025 is one of clear inflection. In Q2 2025, the company reported its first-ever revenue-generating quarter following its strategic Rocket Doctor Inc. acquisition. Revenues reached $0.5 million for the quarter, driven almost entirely by digital health platform and marketplace fees. Perhaps even more striking, Rocket Doctor’s gross margin hit a remarkable 89%, impressive by any SaaS or healthcare technology standard. For investors, this demonstrates that as revenue scales, the incremental returns to ownership could be highly attractive.

Like most high-growth technology players, Rocket Doctor AI is currently investing heavily in product development, sales, and partnerships - resulting in an adjusted EBITDA loss of $1.7 million for the quarter. However, the company’s gross margin profile and its stated focus on scaling its SaaS and B2B2C (business-to-business-to-consumer) offering suggest material operating leverage as patient and provider use continues to ramp.

NIH Grant Offers Validation

In October 2025, Rocket Doctor AI (through its US-based subsidiary Treatment.com Inc.) in collaboration with Rush River Research secured a $2 million Small Business Innovation Grant from the National Institutes of Health (NIH). The grant is intended to help communities “transform how AI collects medical history.” This award highlights both Rocket Doctor’s leadership in clinical-grade AI and its ability to partner competitively access high-value federal funding. The NIH’s recognition serves as a validation of Rocket Doctor’s Global Library of Medicine (GLM), a proprietary, clinician-curated knowledge base that underpins the company’s AI-supported diagnostic and patient history tools.

Investors should note the long-term significance of this grant. Not only does it foster technical advances, but it also opens doors for a wider range of collaborations with investors, academic institutions, specialty networks, and government payers. Such relationships are critical for breaking into and scaling within the highly regulated healthcare sector.

Explosive Growth in AI Healthcare

Rocket Doctor AI is positioning itself in a sector experiencing exponential growth. The global AI healthcare market is projected to soar from $26.6 billion in 2024 to $187.7 billion by 2030, compounding at an eye-popping 38.6% annual rate. In North America, adoption is leading the way, with public and private health providers across the U.S. rapidly bringing AI-powered care management, diagnostics, and remote monitoring to millions. In addition to efficiency gains, persistent healthcare worker shortages make AI solutions essential for enabling continuous and scalable care without sacrificing quality.

AI-driven healthcare delivery goes far beyond video calls. Rocket Doctor AI’s platform integrates large language models, clinical-grade data, and remote-connected devices, enabling physicians to manage urgent care, chronic conditions, mental health, and preventive medicine all on one system. Through its GLM, Rocket Doctor AI provides diagnostic support to clinicians, helping them make well-informed, timely decisions even in complex cases.

Why Investors Are Watching

Rocket Doctor AI’s recent milestones signal more than just commercial traction, they reveal a business with the competitive assets and operating model needed to be a leader in the AI-driven healthcare revolution. Key differentiators for investors include its high-margin SaaS platform, expanding base of covered and paying patients, and the ability to win significant external validation and non-dilutive funding.

The company’s push into B2B and B2G (business-to-government) partnerships is creating a basis for expanding its revenue stability, enabling recurrent and scalable income streams beyond direct-to-consumer telehealth. As Rocket Doctor AI grows its projected national footprint, recurring insurer contracts and deepening federal relationships are a recipe for resilient, high-margin growth.

For investors, Rocket Doctor AI offers a compelling opportunity to participate in the powerful intersection of healthcare, artificial intelligence, and cloud-based delivery. With its proven operating platform, growing roster of patients and payers, and high-value IP foundation, the company stands out as a prospective next-generation healthcare leader.

As AI healthcare spending accelerates, companies like Rocket Doctor AI are poised to capture a meaningful share of the opportunity. The coming quarters could bring both revenue gains and further market recognition as the company makes inroads into the vast addressable market for clinician-led, AI-powered virtual care.